Mersana Therapeutics (MRSN) Tops Q4 EPS by 5c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BMO starts chip stocks coverage: Here are its preferred picks
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue